Revvity

The exceptionally low pricing power score of 8/100 for Revvity is a significant concern, especially within the healthcare equipment industry where specialized products can sometimes command premiums.

This indicates the company operates in highly competitive segments or offers products that are susceptible to commoditization and intense customer negotiation. Despite a TTM Operating Margin of 11.5% and TTM Net Margin of 7.4%, these margins are likely achieved through cost management rather than robust pricing leverage.

The divestiture of the AFES business might have also removed higher-margin, less price-sensitive product lines, leaving a portfolio with greater exposure to pricing pressures.

Sustaining or growing profitability will prove challenging if the company cannot differentiate its offerings sufficiently to justify higher prices or maintain favorable terms with large institutional buyers and healthcare systems.